Obermatt
See Similar Stocks →

Flags

Financial distress

Exagen

NMQ:XGN · US30068X1037
BiotechnologySmall

360

49
Profit price80
Owner Earnings Yield1
Dividend Yield1
Price/Sales91
EV / Gross Profit67
Price/Book95
Return on Capital74
Cash Return on Capital31
Return on Equity14
Profit margins97
Accruals50
Owner Earnings Margin80
Sales growth34
Profit growth67
Reinvestment61
Price momentum16
Debt load17
Refinancing96
Debt Payback1
Liquidity44
Analyst ratings100
Opinion Changes50
Price Target Upside20
Market mood1
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Exagen doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2002
Employees194
Websiteexagen.com
ISINUS30068X1037
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
CardiovascularChronic DiseasesBiomedical EngineeringRheumatologyInflammationHealth DiagnosticsImmunologyNephrologyBiotechnologyGeneticsMedical

Description

Exagen Inc. is a medical technology company. The company primarily focuses on the design, development, and commercialization of a next-generation portfolio of innovative testing products under the AVISE brand, which allow for the differential diagno…

Analysis

Middle-of-the-road

Exagen Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
64
2026

All-time high

64

Jun 2026

All-time low

13

Mar 2026

Average rank

39

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
91
—
—
—
Price/Earnings
76
—
—
—
Price/Book
95
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
95
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Exagen with its peers
Vor Biopharma
NSQ:VOR
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
AnaptysBio
NSQ:ANAB
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Insmed
NSQ:INSM
51
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
PepGen
NSQ:PEPG
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Janux Therapeutics
NMQ:JANX
41
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Larimar Therapeutics
NMQ:LRMR
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →